Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Alcon Inc.’s ALC UNITY Vitreoretinal Cataract System (“VCS”) has recently received approval from Health Canada. UNITY VCS is ...

Alcon AG plans to acquire Lumithera Inc., adding its photobiomodulation (PBM) device designed to treat early and intermediate ...

This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...

Dry eye affects up to 16 million people in the US, and new treatments aim to mitigate the symptoms that can disrupt quality of life in these patients.

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal ...

Dry eye treatment devices market was valued at US$ 461.01 million in 2024 and is projected to hit the market valuation of US$ 898.78 million by 2033 at a CAGR of 7.7% during the forecast period ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Treating dry eye disease with ocular lubrication can significantly reduce migraine severity as measured by the HIT-6 questionnaire.

Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.